Global Cord Blood Gross Profit

Global Cord Blood posts a gross profit of $1B as of July 2022. That compares with $1B in the prior-year period — up 3.7% year over year. That is below the Healthcare sector average of $66B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Global Cord Blood's gross profit was $1B. The latest reading is $1B — a 3.7% year-over-year increase (period ending July 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $66B is typical. Global Cord Blood's $1B is lower that level. That is roughly 98.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Global Cord Blood's financial statement story. At $1B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CO's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $66B), and (3) consistency with growth and profitability. This page covers the first two; Global Cord Blood's other metric pages and overview cover the third.